Oxaliplatin long-circulating liposomes improved therapeutic index of colorectal carcinoma

BMC Biotechnology

Volumn 11, Issue , 2011, Pages

  Yang, Chuang ^a,b   Liu, Hai Z ^a   Fu, Zhong X ^a   Lu, Wei D ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Third People's Hospital of Mianyang City   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMOR ACTIVITIES; APOPTOSIS; APOPTOTIC RESPONSE; COLORECTAL CARCINOMA; CYTOTOXIC DRUGS; FLUORESCENCE IMAGING; IN-VIVO IMAGING; INCREASED LIFE SPANS; INDUCTION TIME; INTRAVENOUS INJECTIONS; LONG-CIRCULATING LIPOSOMES; MEAN FLUORESCENCE INTENSITIES; OXALIPLATIN; PATHOLOGICAL TISSUE; PROTEIN EXPRESSIONS; SUPPRESSION RATIOS; THERAPEUTIC INDEX; TUMOUR TISSUE;

CELL DEATH; FLUORESCENCE; LIPOSOMES; PHOSPHOLIPIDS;

TUMORS;

LIPOSOME; MACROGOL; MESSENGER RNA; OXALIPLATIN; ANTINEOPLASTIC AGENT; BCL2 PROTEIN, MOUSE; DRUG CARRIER; ONCOPROTEIN; PLATINUM COMPLEX; PROTEIN BAX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SIZE; CELL VIABILITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; FEMALE; FLUORESCENCE IMAGING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIFESPAN; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; BAGG ALBINO MOUSE; COLORECTAL TUMOR; DRUG DELIVERY SYSTEM; DRUG EFFECT; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; INSTRUMENTATION; METABOLISM; METHODOLOGY; NUDE MOUSE; PATHOPHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; COLORECTAL NEOPLASMS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS;

EID: 79952565032     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-11-21     Document Type: Article

References (48)

1. Nobili S, Checcacci D, Filippelli F, Del Buono S, Mazzocchi V, Mazzei T, Mini E. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan-or oxaliplatin-based chemotherapy. J Chemother 2008, 20:622-631.
2. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist 2004, 9:8-12. 10.1634/theoncologist.9-1-8, 14755010.
3. Pessino A, Sobrero A. Optimal treatment of metastatic colorectal cancer, Expert Rev. Anticancer Ther 2006, 6:801-812.
4. Basaki Y, Chikahisa L, Aoyagi K, Miyadera K, Yonekura K, Hashimoto A, Okabe S, Wierzba K, Yamada Y. Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis 2001, 4:163-173. 10.1023/A:1014059528046, 11911014.
5. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed Pharmacother 1989, 43:251-260. 10.1016/0753-3322(89)90004-8, 2790145.
6. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why?. Crit Rev Oncol Hematol 2006, 59:159-168. 10.1016/j.critrevonc.2006.01.001, 16806962.
7. Michor F, Iwasa Y, Lengauer C, Nowak NA. Dynamics of colorectal cancer. Semin Cancer Biol 2005, 15:484-493. 10.1016/j.semcancer.2005.06.005, 16055342.
8. Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 2006, 56:13-16. 10.1159/000094376, 16825773.
9. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther 2007, 6:3019-3027. 10.1158/1535-7163.MCT-07-0615, 18025286.
10. Sun W, Zou W, Huang G, Li A, Zhang N. Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration. J Drug Target 2008, 16:357-365. 10.1080/10611860801927598, 18569280.
11. Dunnick JK, Rooke JD, Aragon S, Kriss JP. Alteration of mammalian cells by interaction with artificial lipid vesicles. Cancer Res 1976, 36:2385-2389.
12. Poste G, Papahadjopoulos D. Lipid vesicles as carriers for introducing materials into cultured cells: influence of vesicle lipid composition on mechanism(s) of vesicle incorporation into cells. Proc Natl Acad Sci USA 1976, 73:1603-1607. 10.1073/pnas.73.5.1603, 430347, 818640.
13. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta 1991, 1066:29-36. 10.1016/0005-2736(91)90246-5, 2065067.
14. Klibanov AL, Maruyama K, Beckerleg AM, Torchilin VP, Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta 1991, 1062:142-148. 10.1016/0005-2736(91)90385-L, 2004104.
15. Allen C, Dos Santos N, Gallagher R, Chiu GN, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci Rep 2002, 22:225-250. 10.1023/A:1020186505848, 12428902.
16. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010, 624:25-37. full_text, 20217587.
17. Yuan F, Dellian M, Fukumura D. Vascular perme-ability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
18. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71:409-419. 10.1016/j.ejpb.2008.11.010, 19070661.
19. Fang J, Sawa T, Maeda H. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 2003, 519:29-49. full_text, 12675206.
20. HHarrington KJ, Lewanski C, Northcote AD, Whittaker J, Peters AM, Vile RG, Stewart JS. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cance 2001, 37:2015-2022.
21. Seiden MV, Muggia F, Astrow A, Matulonis U, Campos S, Roche M, Sivret J, Rusk J, Barrett E. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol 2004, 93:229-232. 10.1016/j.ygyno.2003.12.037, 15047241.
22. Torchilin VP. Recent advances with liposomes as pharmaceutical. carriers. Nat Rev Drug Discov 2005, 4:145-160. 10.1038/nrd1632, 15688077.
23. Desai SK, Naik SR. Preparation, relative toxicity, chemotherapeutic activity, and pharmacokinetics of liposomal SJA-95: a new polyene macrolide antibiotic. J Liposome Res 2008, 18:279-92. 10.1080/08982100802457336, 18972246.
24. Rouf MA, Vural I, Renoir JM, Hincal AA. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J Liposome Res 2009, 19:322-31. 10.3109/08982100902963043, 19863167.
25. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA 1988, 85:6949-6953. 10.1073/pnas.85.18.6949, 282096, 3413128.
26. Gabizon AA. Stealth liposomes and tumor targeting: a step further in the quest for the magic bullet. Clin Cancer Res 2001, 7:223-225.
27. Zalipsky S, Brandeis E, Newman MS, Woodle MC. Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett 53:71-74. 994.
28. Cheong I, Zhou S. Tumor-specific liposomal drug release mediated by liposomase. Methods Enzymol 2009, 465:251-265. full_text, 19913171.
29. Singh S. Nanomedicine-nanoscale drugs and delivery systems. J Nanosci Nanotechnol 2010, 10:7906-1918. 10.1166/jnn.2010.3617, 21121278.
30. Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 2009, 137:8-14. 10.1016/j.jconrel.2009.02.023, 19285528.
31. Zhang G, Yang Z, Lu W, Zhang R, Huang Q, Tian M, Li L, Liang D, Li C. Influence of anchoring ligands and particle size on the colloidal stability and in vivo biodistribution of polyethylene glycol-coated gold nanoparticles in tumor-xenografted mice. Biomaterials 2009, 30:1928-1936. 10.1016/j.biomaterials.2008.12.038, 2745599, 19131103.
32. Thurston G, Mclean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, Mcdonald DM. Cationic liposomes target angiogenic endothelial cells in tumours and chronic inflammation in mice. J Clin Invest 1998, 101:1401-1413. 10.1172/JCI965, 508718, 9525983.
33. Yuan F, Dellian M, Fukumura D. Vascular perme-ability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
34. Doi Y, Okada T, Matsumoto H, Ichihara M, Ishida T, Kiwada H. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model. Cancer Sci 2010, 101:2470-2475. 10.1111/j.1349-7006.2010.01678.x, 20731663.
35. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: molecular charge dependence. British Journal of Cancer 2000, 82:1513-1518. 10.1054/bjoc.1999.1171, 2363402, 10789717.
36. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515. 10.1021/mp800051m, 2663893, 18672949.
37. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003, 104:121-129. 10.1002/ijc.10907, 12532428.
38. John C, . Reed Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008, 111:3322-3330. 10.1182/blood-2007-09-078162, 2275002, 18362212, Reed.
39. Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T, Green DR. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. PNAS 2008, 105:20327-20332. 10.1073/pnas.0808036105, 2629294, 19074266.
40. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res 2002, 62:4282-4288.
41. Jain A, Jain SK, Ganesh N, Barve J, Beg AM. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine: NBM 2010, 6:179-190.
42. Abu-Lila A, Suzuki T, Doi Y, Ishida T, Kiwada H. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. J Control Release 2009, 134:18-25. 10.1016/j.jconrel.2008.10.018, 19010364.
43. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS. Distribution of Liposomes into Brain and Rat Brain Tumor Models by Convection-Enhanced Delivery Monitored with Magnetic Resonance Imaging. Cancer research 2004, 64:2572-2579. 10.1158/0008-5472.CAN-03-3631, 15059914.
44. Katriina L, Riitta M, Jari K, Ilpo J, Stina S. Intracellular Distribution of Oligonucleotides Delivered by Cationic Liposomes: Light and Electron Microscopic Study. The Journal of Histochemistry & Cytochemistry 1997, 45:265-274.
45. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, Ahmad I. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEPETU) formulation. Eur J Pharm Biopharm 2005, 59:177-187. 10.1016/j.ejpb.2004.06.009, 15567316.
46. El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer 2005, 117:409-417. 10.1002/ijc.21205, 15906362.
47. Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, Jo HG, Park JH, Choi K, Jeong SY, Park RW, Kim IS, Kim K, Kwon IC. Antitumor efficacy of cisplatin-loadedglycol chitosan nanoparticles in tumor-bearing mice. J Control Release 2008, 127:41-49. 10.1016/j.jconrel.2007.12.014, 18234388.
48. Kviecinski MR, Felipe KB, Schoenfelder T, de Lemos Wiese LP, Rossi MH, Goncalez E, Felicio JD, Filho DW, Pedrosa RC. Study of the antitumor potential of Bidens pilosa (Asteraceae) used in Brazilian folk medicine. J Ethnopharmacol 2008, 117:69-75. 10.1016/j.jep.2008.01.017, 18342465.